Status:
COMPLETED
Esketamine on Postpartum Depression in Cesarean Section Women
Lead Sponsor:
Ailin Luo
Collaborating Sponsors:
Maternal and Child Health Hospital of Hubei Province
Jingmen No.1 People's Hospital
Conditions:
Esketamine
Postpartum Depression
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug
Detailed Description
Studies have shown that esketamine can treat clinical refractory depression, the drug takes effect quickly, can quickly eliminate the patient's suicide intention, low-dose maintenance treatment is con...
Eligibility Criteria
Inclusion
- Elective cesarean section;
- 18-40 years;
- Primipara;
- Singleton pregnancy;
- Sign informed consent.
Exclusion
- American Society of Anesthesiologists (ASA) grade III and above;
- Intracranial hypertension;
- Hypertension;
- Severe heart disease;
- Hyperthyroidism patients without treatment or insufficient treatment;
- Liver and kidney dysfunction;
- Preeclampsia or eclampsia;
- Mental disorder, mental retardation;
- Drug abuse and alcoholism;
- Contraindication of intraspinal anesthesia;
- The preoperative EPDS score ≥10;
- Participated in other clinical studies.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT04860661
Start Date
May 1 2021
End Date
March 31 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital
Wuhan, Hubei, China, 430000